This page shows the latest Shingrix news and features for those working in and with pharma, biotech and healthcare.
Looking at the fourth quarter numbers, pharma sales slumped 5% to £4.6bn, but there was an encouraging 18% gain for vaccines to £1.74bn thanks to strong growth for Shingrix,
Key Q3 drivers include Shingrix vaccine and asthma drug Nucala. GlaxoSmithKline has raised its profit forecast for the second consecutive quarter thanks to the strong sales of its shingles vaccine Shingrix ... Also bringing the forecast up is GSK’s
The decision to drop the two vaccines came as another of GSK’s vaccines – Shingrix for shingles – saw its sales rocket in the first three months of the year, reaching £357m ( ... Shingrix’ performance helped GSK’s vaccine unit to a 23% sales
Nevertheless, there is expected to be strong performances from its Shingrix vaccine and next-generation respiratory drug Ellipta, which have both been the focus of GSK’s new drive towards commercial
Meanwhile, vaccines grew 12% to £1.92bn led by new shingles vaccine Shingrix which contributed $286m in the quarter.
shingles vaccine Shingrix and HIV treatment Juluca.
More from news
Approximately 9 fully matching, plus 19 partially matching documents found.
contain the adjuvant QS-21 Stimulon. In October 2017 GSK's QS-21 Stimulon herpes zoster vaccine, Shingrix, was approved by the FDA. GSK's malarial vaccine, Mosquirix which also contains
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
WE’RE ON A MISSION
To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....